NCT05616650 2026-03-13
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
25 trials2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid × 1 year × Clear all
NCT05849298 2026-03-03
PSMACare
Novartis
Phase 2 Active not recruiting
NCT04461509 2026-02-20
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT03861676 2026-02-13
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Recruiting
NCT04573231 2026-02-05
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
University of Wisconsin, Madison
Phase 2 Recruiting
NCT03173924 2026-01-21
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03181867 2026-01-21
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Enrolling by invitation
NCT06085664 2026-01-15
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03976843 2025-12-18
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05470699 2025-12-17
RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT07084909 2025-12-10
HARRIER
Lantheus Medical Imaging
Phase 2/3 Withdrawn
NCT05919329 2025-10-24
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
OHSU Knight Cancer Institute
Phase 4 Recruiting
NCT04910425 2025-10-21
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT06499870 2025-10-21
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT03253744 2025-10-08
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04687969 2025-09-25
Multimodal Machine Learning Characterization of Solid Tumors
Massachusetts General Hospital
Active not recruiting
NCT06074510 2025-09-11
MIRROR
Lantheus Medical Imaging
Phase 4 Active not recruiting
NCT03860987 2025-09-08
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05009979 2025-08-28
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT06361810 2025-08-19
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Withdrawn
NCT05155046 2025-08-01
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05095519 2025-07-16
HepaSMART
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT06904313 2025-06-04
Ultralow Dose PET Imaging for PSMA Expression
Nuclear Imaging Institute
Phase 2 Recruiting
NCT03392181 2025-05-23
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
Northwestern University
Phase EARLY_PHASE1 Active not recruiting
NCT04390880 2025-05-16
PROSPYL
VA Greater Los Angeles Healthcare System
Phase 2 Completed